Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Pacritinib (Vonjo): A Key JAK Inhibitor for Cytopenic Myelofibrosis
Credits for sharing: Dr. Omar Albanyan
Pacritinib is uniquely developed for patients with Myelofibrosis and severe thrombocytopenia and/or anemia.
Why Pacritinib Is Different
Key Targets
- JAK2
- IRAK1
- ACVR1
- Minimal JAK1 inhibition (JAK1-sparing)
JAK1-sparing may help reduce myelosuppression while preserving immune signaling.
Benefits in Thrombocytopenic MF
Approved for symptomatic myelofibrosis with platelet counts less than 50 ×10⁹/L
- Effective spleen volume reduction
- Improvement in constitutional symptoms
- No dose reduction required in severe thrombocytopenia
Benefits in Anemic MF
ACVR1 inhibition may:
- Reduce hepcidin levels
- Increase iron availability
- Improve erythropoiesis
- Enhance transfusion independence
In vitro data suggest stronger ACVR1 inhibition compared with Momelotinib, although this does not confirm superior clinical efficacy.
Key Clinical Trials
- PERSIST-2
Demonstrated significant spleen and symptom responses in thrombocytopenic MF. - PACIFICA
Confirmed efficacy and manageable safety in patients with platelet counts <50 ×10⁹/L.
Ideal Patient Profile
- Platelet less than 50 ×10⁹/L
- Concurrent anemia or transfusion dependence
- Massive splenomegaly
- Significant constitutional symptoms
- Unsuitability for Ruxolitinib or Fedratinib because of thrombocytopenia
Common Adverse Events
- Diarrhea (most common; usually early and manageable)
- Nausea
- Anemia
- Thrombocytopenia
- Peripheral edema
Clinical Pearl
Pacritinib is often considered the preferred JAK inhibitor when severe thrombocytopenia and anemia coexist.
MCQ
Which feature most distinguishes Pacritinib from other JAK inhibitors?
- Intravenous administration
- Potent JAK1 inhibition
- Use in platelet counts <50 ×10⁹/L
- Causes profound myelosuppression
Answer: C. Use in platelet counts <50 ×10⁹/L
Key References
- NCCN Guidelines for Myeloproliferative Neoplasms
- Pacritinib (Vonjo) Prescribing Information
- PERSIST-2 Trial Publication
- PACIFICA Trial Update”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow
-
May 23, 2026, 16:19Sitthiwut Chaturamaytanon: 6 Days Advancing aHUS and PNH Care in Thailand Through Collaboration
-
May 23, 2026, 14:48Sam Zeraatain Nejad Davani: Off-Pump Surgery for COVID-19 Right Atrial Thrombosis
-
May 23, 2026, 14:42How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH